PE20212369A1 - Receptores de antigenos quimericos resistentes a rituximab y usos de estos - Google Patents
Receptores de antigenos quimericos resistentes a rituximab y usos de estosInfo
- Publication number
- PE20212369A1 PE20212369A1 PE2021001764A PE2021001764A PE20212369A1 PE 20212369 A1 PE20212369 A1 PE 20212369A1 PE 2021001764 A PE2021001764 A PE 2021001764A PE 2021001764 A PE2021001764 A PE 2021001764A PE 20212369 A1 PE20212369 A1 PE 20212369A1
- Authority
- PE
- Peru
- Prior art keywords
- chimeric antigen
- rituximab
- car
- antigen receptors
- polypeptide
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 7
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 abstract 2
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 abstract 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000001295 genetical effect Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960004641 rituximab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE A RECEPTORES DE ANTIGENOS QUIMERICOS (CAR) QUE COMPRENDEN UNA MOLECULA DE FIJACION AL ANTIGENO QUE SE FIJA A CD19. TAMBIEN SE REFIERE A UN POLINUCLEOTIDO AISLADO QUE CODIFICA UN POLIPEPTIDO QUE COMPRENDE UN RECEPTOR DE ANTIGENO QUIMERICO (CAR) ANTI-CD19 QUE ES AL MENOS UN 70 % IDENTICO A SEQ ID NO: 9, EN DONDE EL POLIPEPTIDO NO COMPRENDE UN SITIO DE FIJACION A RITUXIMAB, Y EN DONDE EL POLINUCLEOTIDO COMPRENDE UN PROMOTOR EF1A CORTO QUE ES CAPAZ DE EXPRESAR EL RECEPTOR DE ANTIGENO QUIMERICO (CAR) ANTI-CD19 EN UN LINFOCITO T DE MAMIFERO, EN DONDE EL PROMOTOR EF1A CORTO COMPRENDE UN INTRON COMPRENDIDO POR SEQ ID NO:39; Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA CELULA INMUNITARIA DISENADA POR INGENIERIA GENETICA QUE COMPRENDE EL POLINUCLEOTIDO AISLADO.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962839455P | 2019-04-26 | 2019-04-26 | |
US202063005041P | 2020-04-03 | 2020-04-03 | |
PCT/US2020/029775 WO2020219848A1 (en) | 2019-04-26 | 2020-04-24 | Rituximab-resistant chimeric antigen receptors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20212369A1 true PE20212369A1 (es) | 2021-12-21 |
Family
ID=70847489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021001764A PE20212369A1 (es) | 2019-04-26 | 2020-04-24 | Receptores de antigenos quimericos resistentes a rituximab y usos de estos |
Country Status (18)
Country | Link |
---|---|
US (1) | US11896617B2 (es) |
EP (2) | EP4295851A3 (es) |
JP (1) | JP2022532996A (es) |
KR (1) | KR20220004076A (es) |
CN (1) | CN113728001A (es) |
AU (1) | AU2020263495A1 (es) |
BR (1) | BR112021021178A2 (es) |
CA (1) | CA3134308A1 (es) |
CO (1) | CO2021014121A2 (es) |
DK (1) | DK3959235T3 (es) |
ES (1) | ES2961314T3 (es) |
FI (1) | FI3959235T3 (es) |
IL (1) | IL287487A (es) |
MX (1) | MX2021012820A (es) |
PE (1) | PE20212369A1 (es) |
SG (1) | SG11202111031RA (es) |
TW (1) | TW202106704A (es) |
WO (1) | WO2020219848A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117396607A (zh) | 2020-12-30 | 2024-01-12 | 阿劳诺斯治疗公司 | 包含多顺反子表达盒的重组载体及其使用方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
DK1257632T3 (da) | 2000-02-24 | 2008-01-28 | Xcyte Therapies Inc | Samtidig stimulering og opkoncentrering af celler |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
NZ532060A (en) | 2001-10-02 | 2005-11-25 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
US9024028B2 (en) | 2011-01-26 | 2015-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for the synthesis of multimerizing agents |
AU2012230780B2 (en) | 2011-03-23 | 2016-10-27 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
WO2013176916A1 (en) * | 2012-05-25 | 2013-11-28 | Roman Galetto | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
CA2901115A1 (en) | 2013-02-15 | 2014-08-21 | The Regents Of The University Of California | Heterodimeric conditionally active chimeric antigen receptor and methods of use thereof |
WO2014151960A2 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
CN105431532B (zh) | 2013-05-13 | 2021-04-06 | 瑟勒提斯公司 | Cd19特异性嵌合抗原受体及其用途 |
DK3027204T3 (da) | 2013-07-29 | 2022-04-19 | 2Seventy Bio Inc | Flerdelte signaleringsproteiner og anvendelser deraf |
EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
CA2937938A1 (en) | 2014-02-04 | 2015-08-13 | Kite Pharma, Inc. | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
CN111849912B (zh) | 2014-02-14 | 2024-03-15 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
JP6868554B2 (ja) * | 2014-09-02 | 2021-05-12 | ベリカム ファーマシューティカルズ, インコーポレイテッド | MyD88およびCD40ポリペプチドによるキメラ抗原受容体の共刺激 |
US11014989B2 (en) | 2015-01-26 | 2021-05-25 | Cellectis | Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy |
GB201518792D0 (en) * | 2015-10-23 | 2015-12-09 | Univ Manchester | Production of proteins |
WO2017103613A1 (en) | 2015-12-18 | 2017-06-22 | Ucl Business Plc | Treatment |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
GB201609597D0 (en) | 2016-06-01 | 2016-07-13 | Univ Sheffield | Therapy |
SG11201907922PA (en) * | 2017-03-03 | 2019-09-27 | Obsidian Therapeutics Inc | Cd19 compositions and methods for immunotherapy |
EP3784785A4 (en) | 2018-04-23 | 2022-02-16 | Duke University | DOWNREGULATION OF SNCA EXPRESSION BY TARGETED EDITING OF DNA METHYLATION |
SG11202101996QA (en) * | 2018-08-28 | 2021-03-30 | Immunotech Biopharm Co Ltd | Improved therapeutic t cell |
-
2020
- 2020-04-24 PE PE2021001764A patent/PE20212369A1/es unknown
- 2020-04-24 SG SG11202111031RA patent/SG11202111031RA/en unknown
- 2020-04-24 ES ES20728258T patent/ES2961314T3/es active Active
- 2020-04-24 JP JP2021563352A patent/JP2022532996A/ja active Pending
- 2020-04-24 AU AU2020263495A patent/AU2020263495A1/en active Pending
- 2020-04-24 EP EP23186544.5A patent/EP4295851A3/en active Pending
- 2020-04-24 MX MX2021012820A patent/MX2021012820A/es unknown
- 2020-04-24 TW TW109113823A patent/TW202106704A/zh unknown
- 2020-04-24 CA CA3134308A patent/CA3134308A1/en active Pending
- 2020-04-24 EP EP20728258.3A patent/EP3959235B1/en active Active
- 2020-04-24 US US16/857,573 patent/US11896617B2/en active Active
- 2020-04-24 CN CN202080031593.1A patent/CN113728001A/zh active Pending
- 2020-04-24 FI FIEP20728258.3T patent/FI3959235T3/fi active
- 2020-04-24 KR KR1020217036085A patent/KR20220004076A/ko unknown
- 2020-04-24 DK DK20728258.3T patent/DK3959235T3/da active
- 2020-04-24 BR BR112021021178A patent/BR112021021178A2/pt unknown
- 2020-04-24 WO PCT/US2020/029775 patent/WO2020219848A1/en active Application Filing
-
2021
- 2021-10-21 IL IL287487A patent/IL287487A/en unknown
- 2021-10-22 CO CONC2021/0014121A patent/CO2021014121A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022532996A (ja) | 2022-07-21 |
ES2961314T3 (es) | 2024-03-11 |
CN113728001A (zh) | 2021-11-30 |
EP4295851A2 (en) | 2023-12-27 |
BR112021021178A2 (pt) | 2022-03-15 |
WO2020219848A1 (en) | 2020-10-29 |
IL287487A (en) | 2021-12-01 |
US11896617B2 (en) | 2024-02-13 |
KR20220004076A (ko) | 2022-01-11 |
EP4295851A3 (en) | 2024-02-14 |
SG11202111031RA (en) | 2021-11-29 |
CA3134308A1 (en) | 2020-10-29 |
CO2021014121A2 (es) | 2021-10-29 |
FI3959235T3 (fi) | 2023-09-27 |
US20200384026A1 (en) | 2020-12-10 |
TW202106704A (zh) | 2021-02-16 |
DK3959235T3 (da) | 2023-10-16 |
EP3959235B1 (en) | 2023-07-26 |
MX2021012820A (es) | 2021-11-25 |
AU2020263495A1 (en) | 2021-10-28 |
EP3959235A1 (en) | 2022-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190169303A1 (en) | Humanized Anti-OX40 Antibodies and Uses Thereof | |
JP6306201B2 (ja) | インターロイキン−2融合タンパク質及びその使用 | |
PE20081625A1 (es) | Proteinas de union al antigeno del receptor a de la il-17 | |
PE20230821A1 (es) | Anticuerpos anti-ccr8 para el tratamiento del cancer | |
AR075047A1 (es) | Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit. | |
AR052374A2 (es) | Una composicion que comprende un receptor ob variante 12.1, una molecula de acido nucleico que codifica dicho receptor ligado operativamente a un promotor, un vector de expresion, una celula huesped, un receptor ob quimerico fusionado a una inmunologlubina y anticuerpo agonista monoclonal que se lig | |
PE20220489A1 (es) | Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso | |
ES2545895T3 (es) | Proteína de fusión anticancerígena | |
PE20080694A1 (es) | Anticuerpo de c-kit humanizado | |
AR080291A1 (es) | Anticuerpos antagonistas anti receptor de il-7 y procedimientos | |
RU2015110250A (ru) | ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ | |
WO2013151670A3 (en) | Modified polynucleotides for the production of nuclear proteins | |
NZ724904A (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
RU2014141505A (ru) | Способ получения поверхностно-активных пептидов | |
PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
NZ781138A (en) | Anti-vegf protein compositions and methods for producing the same | |
CA2975017A1 (en) | Therapeutic and diagnostic agents | |
PE20171652A1 (es) | Nuevas proteinas especificas para pioverdina y pioquelina | |
PE20212369A1 (es) | Receptores de antigenos quimericos resistentes a rituximab y usos de estos | |
JP2016520619A5 (es) | ||
HRP20221142T1 (hr) | Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću | |
Hoffman et al. | Isolation and sequence of a tomato cDNA clone encoding subunit II of the photosystem I reaction center | |
AR123405A1 (es) | Anticuerpos anti-il-36 y métodos de uso de estos | |
PE20191662A1 (es) | Anticuerpos anti-il-5 | |
Oda et al. | Binding characteristics of antibodies to the TSH receptor |